1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,625 | 0,629 | 21:38 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 55,00 | +4,29 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| GENMAB | 229,10 | +0,75 % | Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,950 | +1,02 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,238 | -7,03 % | Wie MustGrow Biologics mit patentierter Biowirkstoff-Technologie von der Neuausrichtung der Agrochemie-Riesen profitiert - Druck für Bayer und Corteva | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Extreme Hitzewellen, immer schlechtere Böden und strenge gesetzliche Grenzwerte für chemisch-synthetische Pflanzenschutzmittel - die... ► Artikel lesen | |
| VERICEL | 35,200 | -1,12 % | Vericel Corporation: Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,890 | +5,09 % | Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial | Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject... ► Artikel lesen | |
| FAETH THERAPEUTICS | 26,400 | +10,00 % | H.C. Wainwright initiates Faeth Therapeutics stock coverage with buy rating | ||
| BIOXCEL THERAPEUTICS | 1,170 | +4,46 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| REGENXBIO | 8,900 | +1,71 % | REGENXBIO Inc.: REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II | FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE® study will be reviewed on an expedited basis for approval via the accelerated... ► Artikel lesen | |
| AKEBIA | 0,932 | -2,10 % | Akebia Therapeutics, Inc. - 8-K, Current Report | ||
| ZEVRA THERAPEUTICS | 11,350 | -0,87 % | Zevra Therapeutics Announces Publication of Positive MIPLYFFA Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) | BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 8,800 | +5,39 % | Fennec Pharmaceuticals Inc: Fennec grants option to buy 15,000 shares | ||
| CORVUS PHARMACEUTICALS | 11,350 | +3,23 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China | SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in... ► Artikel lesen | |
| REVANCE THERAPEUTICS | - | - | Revance taps dancer Julianne Hough to choreograph social media push for Botox rival | ||
| CARTESIAN THERAPEUTICS | 8,300 | 0,00 % | Cartesian Therapeutics, Inc. - 8-K, Current Report |
SYNTHAVERSE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,626 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.